SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Ada Lovelace Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientAda Lovelace
Date of birth1815-12-10
IdentifiersMRN HR-NI031-SYN-TD; SSN (made up) 000-31-6729
Document date2026-11-01
AuthorConstance Whitley-Adeyemi, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

New patient visit for abnormal bleeding and pelvic pain: history, speculum examination and cervical biopsy, blood count and iron studies, conversion of opium tincture to measured oral morphine, an iron infusion, and a gynecologic oncology referral. Concerns: She wants to know plainly what the bleeding means and to make her own decisions; She wants her mornings clear-headed for her mathematical work and fears that stronger pain medicine will cloud her mind. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Opium tincture (100 mg/mL opium, equivalent to 10 mg/mL morphine), 0.5 mL by mouth four to six times a day as needed for pain0.5 mL four to six times a day as neededOral route1849-06-03 to 1851-06-02completedS
Morphine sulfate oral solution 2 mg/mL, 5 mg (2.5 mL by oral syringe) every 4 hours as needed for pain5 mg every 4 hours as neededOral route1851-06-02activeS
Morphine sulfate extended-release 15 mg tablet, one tablet by mouth every 12 hours; swallow wholeevery 12 hoursOral route1851-06-16 to 1851-10-20completedS
Morphine sulfate extended-release 15 mg tablet, one tablet by mouth at night, for two weeks, then stoponce at night for two weeks, then stopOral route1851-10-20activeS
Naloxone 4 mg nasal spray, one spray in a nostril for suspected opioid overdose; call 911one spray as needed for suspected overdose; repeat after 2 to 3 minutes if neededNasal route1851-06-02activeS
Senna 8.6 mg tablet, two tablets by mouth at nighttwo tablets at nightOral route1851-06-02activeS
Polyethylene glycol 3350, 17 g in water by mouth once or twice a dayonce daily, up to twice dailyOral route1851-06-02activeS
Acetaminophen 500 mg tablet, two tablets by mouth three times a day1 g three times a dayOral route1851-06-02activeS
Ferric carboxymaltose 750 mg intravenous infusion, two doses at the first two visits750 mg on two occasions two weeks apartIntravenous route1851-06-02 to 1851-06-17completedS
Pembrolizumab 200 mg intravenously every 3 weeksevery 3 weeksIntravenous route1851-06-30activeS
Carboplatin, dose to an AUC of 5 (650 mg), intravenously every 3 weeks for six cyclesevery 3 weeks for six cyclesIntravenous route1851-06-30 to 1851-10-13completedS
Paclitaxel 175 mg/m2 (275 mg) intravenously every 3 weeks for six cycles, with premedicationevery 3 weeks for six cyclesIntravenous route1851-06-30 to 1851-10-13completedS
Ondansetron 8 mg tablet, one tablet by mouth twice a day for three days after each chemotherapy cycle, then as neededtwice a day for three days after each cycle, then as neededOral route1851-06-30activeS

Procedures

ProcedureDatesStatusEvidence
Speculum examination with punch biopsy of an exophytic friable cervical mass, with a specimen for high-risk HPV typing; hemostasis with ferric subsulfate1851-06-02 to 1851-06-02completedS
MRI of the pelvis: 5.2 cm endocervical tumor with left parametrial invasion, not reaching the pelvic sidewall; no hydronephrosis; enlarged left external iliac lymph node1851-06-09 to 1851-06-09completedS
FDG PET-CT: avid cervical tumor; avid left pelvic and para-aortic lymph nodes; six avid nodules in both lungs up to 1.4 cm; no bone or liver lesions1851-06-11 to 1851-06-11completedS
CT-guided core biopsy of a right lower lobe lung nodule: metastatic adenocarcinoma, p16 strongly positive and HPV 18 detected, matching the cervical primary; small apical pneumothorax not needing treatment1851-06-19 to 1851-06-19completedS
Palliative external beam radiation to the pelvis for bleeding and pain, 20 Gy in 5 fractions over five days1851-06-22 to 1851-06-26completedS
CT of chest, abdomen and pelvis after four cycles: partial response by RECIST 1.1, with the cervical tumor 3.1 cm, lung nodules smaller (largest 0.6 cm) and two resolved, para-aortic nodes below 1 cm; no new lesions1851-08-31 to 1851-08-31completedS
Advance care planning conversation, about 30 minutes1851-08-18 to 1851-08-18completedS

Immunizations

DateVaccineStatusEvidence
1851-08-18Pneumococcal conjugate vaccine (PCV20)completedS
1851-08-18Recombinant zoster vaccine, dose 1 of 2completedS
1851-08-18Tdap vaccinecompletedS
1851-08-18Hepatitis B vaccine, CpG-adjuvanted (two-dose series), dose 1 of 2completedS
1851-10-20Influenza vaccine, inactivated, trivalentcompletedS
1851-10-20COVID-19 mRNA vaccine, current seasoncompletedS
1851-10-20Recombinant zoster vaccine, dose 2 of 2completedS
1851-10-20Hepatitis B vaccine, CpG-adjuvanted (two-dose series), dose 2 of 2completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1829Measles at 13, with a long recovery and about a year in bedD (CLM-0002)
1837Cholera at 21, followed by lingering asthma and digestive problemsD (CLM-0004)
from about 1843Chronic ill health from her late twenties, with episodes she called heart or rheumatic attacks, treated with several medicines including laudanum and opiumD (CLM-0005, CLM-0007)

Family History

RelativeConditionAge at deathEvidence
fatherA poet; died at 36; cause not recorded in the cited sourceD (CLM-0001)

Health Concerns

ConcernStatusEvidence
She wants to know plainly what the bleeding means and to make her own decisionsactiveS
She wants her mornings clear-headed for her mathematical work and fears that stronger pain medicine will cloud her mindactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 10.9 on 1851-10-20; MCV [Entitic mean volume] in Red Blood Cells by Automated count 74 on 1851-06-02; Leukocytes [#/volume] in Blood by Automated count 4.2 on 1851-10-20; Platelets [#/volume] in Blood by Automated count 188 on 1851-10-20; Ferritin [Mass/volume] in Serum or Plasma 210 on 1851-09-08; Creatinine [Mass/volume] in Serum or Plasma 0.71 on 1851-10-20; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 1851-10-20; Albumin [Mass/volume] in Serum or Plasma 3.6 on 1851-06-02; Choriogonadotropin.beta subunit [Units/volume] in Serum or Plasma 1 on 1851-06-02; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1846)/1.73 sq M 114 on 1851-10-20; Pain severity - 0-10 verbal numeric rating [Score] - Reported 2 on 1851-10-20; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 5 on 1851-10-20; Thyrotropin [Units/volume] in Serum or Plasma 7.8 on 1851-10-20; Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1 on 1851-10-20; Potassium [Moles/volume] in Serum or Plasma 3.8 on 1851-07-07; Calcium [Mass/volume] in Serum or Plasma 9.3 on 1851-07-07; Neutrophils [#/volume] in Blood by Automated count 2.4 on 1851-10-20; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 2 on 1851-08-18 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Bleeding between periods and after intercourse, with heavier periods, a watery blood-stained discharge and a constant pelvic ache, for about five months; average pain 7 of 10 despite her opium tincture; a friable cervical mass found on examination and biopsied; cause not yet established at intakeresolvedconfirmed N93.8S — Synthetic presenting problem anchored to her documented final illness; superseded by the diagnosis at the second visit.
Iron deficiency anemia from chronic blood loss: hemoglobin 8.4 g/dL, mean cell volume 74 fL, ferritin 5 ng/mL, with tiredness and breathlessness on stairsactiveconfirmed D50.0S — Synthetic modern finding anchored to her documented final illness.
Adenocarcinoma of the endocervix, usual (HPV-associated) type, HPV 18 positive, FIGO 1843 stage IVB: a 5.2 cm tumor with left parametrial invasion, metastases to left pelvic and para-aortic lymph nodes, and bilateral lung metastases on MRI and PET-CT; PD-L1 combined positive score 5, mismatch repair proficient, HER2 1+; treated with palliative pelvic radiation for bleeding and carboplatin, paclitaxel and pembrolizumab, with specialist palliative care from diagnosisactiveconfirmed C53.0S — Synthetic modern diagnosis made at the second visit, anchored to her documented uterine cancer; the cervical site is a synthetic choice.
Cancer-related pelvic pain, nociceptive and visceral, from the cervical tumor and its left parametrial extensionactiveconfirmed G89.3S — Synthetic modern diagnosis made at the second visit.
Long-term prescribed opioid therapy: opium tincture for recurrent pelvic and abdominal pain for about two years, measured at times with a household spoon, converted at intake to measured oral morphine; no opioid use disorder on a DSM-5 assessment; naloxone suppliedactiveconfirmed Z79.891S — Synthetic modern history anchored to her documented laudanum and opium; not a claim about her real dosing.
Drug-induced constipation from long-acting morphine and ondansetron, a week after the first chemotherapy cycle: no bowel movement for five days, with bloating and cramping but passing wind, without vomiting; no bowel obstruction on examination; potassium and calcium normal; resolved with laxativesresolvedconfirmed K59.03S — Synthetic adverse drug effect; not a historical claim.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1851-06-02Hemoglobin [Mass/volume] in Blood8.4g/dL12-15.5 g/dLLowS
1851-06-02MCV [Entitic mean volume] in Red Blood Cells by Automated count74fL80-100 fLLowS
1851-06-02Leukocytes [#/volume] in Blood by Automated count7.810*3/uL4-11 10*3/uLNormalS
1851-06-02Platelets [#/volume] in Blood by Automated count41210*3/uL150-400 10*3/uLHighS
1851-06-02Ferritin [Mass/volume] in Serum or Plasma5ng/mL15-150 ng/mLLowS
1851-06-02Creatinine [Mass/volume] in Serum or Plasma0.68mg/dL0.57-1 mg/dLNormalS
1851-06-02Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma18U/L7-35 U/LNormalS
1851-06-02Albumin [Mass/volume] in Serum or Plasma3.6g/dL3.5-5 g/dLNormalS
1851-06-02Choriogonadotropin.beta subunit [Units/volume] in Serum or Plasma1m[IU]/mLBelow 5 is negativeNormalS
1851-06-02Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1846)/1.73 sq M116mL/min/{1.73_m2}60 or moreNormalS
1851-06-02Pain severity - 0-10 verbal numeric rating [Score] - Reported7{score}S
1851-06-02Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]8{score}S
1851-06-16Hemoglobin [Mass/volume] in Blood9g/dL12-15.5 g/dLLowS
1851-06-16Creatinine [Mass/volume] in Serum or Plasma0.66mg/dL0.57-1 mg/dLNormalS
1851-06-16Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma17U/L7-35 U/LNormalS
1851-06-16Thyrotropin [Units/volume] in Serum or Plasma1.9m[IU]/L0.45-4.5 mIU/LNormalS
1851-06-16Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.2ng/dL0.8-1.8 ng/dLNormalS
1851-06-16Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1846)/1.73 sq M117mL/min/{1.73_m2}60 or moreNormalS
1851-06-16Pain severity - 0-10 verbal numeric rating [Score] - Reported6{score}S
1851-07-07Potassium [Moles/volume] in Serum or Plasma3.8mmol/L3.5-5.1 mmol/LNormalS
1851-07-07Calcium [Mass/volume] in Serum or Plasma9.3mg/dL8.6-10.3 mg/dLNormalS
1851-07-14Hemoglobin [Mass/volume] in Blood9.8g/dL12-15.5 g/dLLowS
1851-07-14Leukocytes [#/volume] in Blood by Automated count4.110*3/uL4-11 10*3/uLNormalS
1851-07-14Neutrophils [#/volume] in Blood by Automated count2.210*3/uL1.8-7.7 10*3/uLNormalS
1851-07-14Platelets [#/volume] in Blood by Automated count23610*3/uL150-400 10*3/uLNormalS
1851-07-14Creatinine [Mass/volume] in Serum or Plasma0.7mg/dL0.57-1 mg/dLNormalS
1851-07-14Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-35 U/LNormalS
1851-07-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1846)/1.73 sq M116mL/min/{1.73_m2}60 or moreNormalS
1851-07-14Pain severity - 0-10 verbal numeric rating [Score] - Reported3{score}S
1851-07-14Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]9{score}S
1851-09-08Hemoglobin [Mass/volume] in Blood10.6g/dL12-15.5 g/dLLowS
1851-09-08Leukocytes [#/volume] in Blood by Automated count3.810*3/uL4-11 10*3/uLLowS
1851-09-08Neutrophils [#/volume] in Blood by Automated count1.910*3/uL1.8-7.7 10*3/uLNormalS
1851-09-08Platelets [#/volume] in Blood by Automated count17210*3/uL150-400 10*3/uLNormalS
1851-09-08Creatinine [Mass/volume] in Serum or Plasma0.72mg/dL0.57-1 mg/dLNormalS
1851-09-08Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L7-35 U/LNormalS
1851-09-08Thyrotropin [Units/volume] in Serum or Plasma3.4m[IU]/L0.45-4.5 mIU/LNormalS
1851-09-08Ferritin [Mass/volume] in Serum or Plasma210ng/mL15-150 ng/mLHighS
1851-09-08Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1846)/1.73 sq M112mL/min/{1.73_m2}60 or moreNormalS
1851-09-08Pain severity - 0-10 verbal numeric rating [Score] - Reported3{score}S
1851-09-08Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
1851-10-20Hemoglobin [Mass/volume] in Blood10.9g/dL12-15.5 g/dLLowS
1851-10-20Leukocytes [#/volume] in Blood by Automated count4.210*3/uL4-11 10*3/uLNormalS
1851-10-20Neutrophils [#/volume] in Blood by Automated count2.410*3/uL1.8-7.7 10*3/uLNormalS
1851-10-20Platelets [#/volume] in Blood by Automated count18810*3/uL150-400 10*3/uLNormalS
1851-10-20Creatinine [Mass/volume] in Serum or Plasma0.71mg/dL0.57-1 mg/dLNormalS
1851-10-20Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-35 U/LNormalS
1851-10-20Thyrotropin [Units/volume] in Serum or Plasma7.8m[IU]/L0.45-4.5 mIU/LHighS
1851-10-20Thyroxine (T4) free [Mass/volume] in Serum or Plasma1ng/dL0.8-1.8 ng/dLNormalS
1851-10-20Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1846)/1.73 sq M114mL/min/{1.73_m2}60 or moreNormalS
1851-10-20Pain severity - 0-10 verbal numeric rating [Score] - Reported2{score}S
1851-10-20Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
1851-08-18Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]2{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
1851-06-02Body height165cmS
1851-06-02Body weight54kgS
1851-06-02Body mass index (BMI) [Ratio]19.8kg/m2S
1851-06-02Systolic blood pressure108mm[Hg]S
1851-06-02Diastolic blood pressure68mm[Hg]S
1851-06-02Heart rate96/minS
1851-06-02Respiratory rate16/minS
1851-06-02Body temperature36.8CelS
1851-06-02Oxygen saturation in Arterial blood by Pulse oximetry98%S
1851-06-16Body height165cmS
1851-06-16Body weight54.2kgS
1851-06-16Body mass index (BMI) [Ratio]19.9kg/m2S
1851-06-16Systolic blood pressure106mm[Hg]S
1851-06-16Diastolic blood pressure66mm[Hg]S
1851-06-16Heart rate92/minS
1851-06-16Respiratory rate16/minS
1851-06-16Body temperature36.7CelS
1851-06-16Oxygen saturation in Arterial blood by Pulse oximetry98%S
1851-07-14Body height165cmS
1851-07-14Body weight53.4kgS
1851-07-14Body mass index (BMI) [Ratio]19.6kg/m2S
1851-07-14Systolic blood pressure110mm[Hg]S
1851-07-14Diastolic blood pressure70mm[Hg]S
1851-07-14Heart rate84/minS
1851-07-14Respiratory rate16/minS
1851-07-14Body temperature36.6CelS
1851-07-14Oxygen saturation in Arterial blood by Pulse oximetry98%S
1851-09-08Body height165cmS
1851-09-08Body weight54kgS
1851-09-08Body mass index (BMI) [Ratio]19.8kg/m2S
1851-09-08Systolic blood pressure112mm[Hg]S
1851-09-08Diastolic blood pressure70mm[Hg]S
1851-09-08Heart rate80/minS
1851-09-08Respiratory rate16/minS
1851-09-08Body temperature36.7CelS
1851-09-08Oxygen saturation in Arterial blood by Pulse oximetry98%S
1851-10-20Body height165cmS
1851-10-20Body weight54.4kgS
1851-10-20Body mass index (BMI) [Ratio]20kg/m2S
1851-10-20Systolic blood pressure114mm[Hg]S
1851-10-20Diastolic blood pressure72mm[Hg]S
1851-10-20Heart rate78/minS
1851-10-20Respiratory rate16/minS
1851-10-20Body temperature36.6CelS
1851-10-20Oxygen saturation in Arterial blood by Pulse oximetry98%S
1851-08-18Body height165cmS
1851-08-18Body weight53.6kgS
1851-08-18Body mass index (BMI) [Ratio]19.7kg/m2S
1851-08-18Systolic blood pressure110mm[Hg]S
1851-08-18Diastolic blood pressure70mm[Hg]S
1851-08-18Heart rate80/minS
1851-08-18Respiratory rate16/minS
1851-08-18Body temperature36.6CelS
1851-08-18Oxygen saturation in Arterial blood by Pulse oximetry98%S
1851-07-07Body height165cmS
1851-07-07Body weight53.8kgS
1851-07-07Body mass index (BMI) [Ratio]19.8kg/m2S
1851-07-07Systolic blood pressure110mm[Hg]S
1851-07-07Diastolic blood pressure70mm[Hg]S
1851-07-07Heart rate88/minS
1851-07-07Respiratory rate16/minS
1851-07-07Body temperature36.7CelS
1851-07-07Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
1851-06-02New patient visit for abnormal bleeding and pelvic pain: history, speculum examination and cervical biopsy, blood count and iron studies, conversion of opium tincture to measured oral morphine, an iron infusion, and a gynecologic oncology referralfinishedS
1851-06-16Two-week follow-up and gynecologic oncology consultation: pathology, MRI and PET-CT, staging, treatment intent, palliative care, and long-acting morphinefinishedS
1851-07-14Six-week review: bleeding and pain after palliative pelvic radiation, the first cycle of chemotherapy with pembrolizumab, blood counts, mood and opioid safetyfinishedS
1851-09-08Fourteen-week review: restaging CT, blood counts, iron and thyroid, pain, and a goals-of-care conversationfinishedS
1851-10-20Twenty-week review after the last chemotherapy cycle: blood counts, thyroid on pembrolizumab, tapering morphine, mood and her workfinishedS
1851-08-18Periodic adult preventive visitfinishedS
1851-07-07Same-day sick visit for constipationfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Gynecologic oncology consultation in two weeks for a friable cervical mass with bleeding and pain, biopsied today: diagnosis, staging, treatment intent, bleeding control, and paincompletedGL-NCCN-CERV-2026, GL-FIGO-2018S
Stop opium tincture and change to measured oral morphine solution 5 mg every 4 hours as needed with an oral syringe, with acetaminophen, senna and polyethylene glycol, a naloxone nasal spray, a prescription monitoring check, locked storage, one prescriber, and review in two weekscompletedGL-ASCO-OPIOID-2023, GL-CDC-OPIOID-2022S
Iron deficiency anemia: ferric carboxymaltose 750 mg intravenously today and in two weeks, with a blood count at each visit and ferritin 6 to 8 weeks after the infusionscompletedGL-CMID-2026S
Blood tests: blood count, ferritin, creatinine, ALT, albumin and a pregnancy test; HIV, hepatitis B and hepatitis C tests before any cancer treatment; PHQ-9completedGL-ASCO-HBV-2020, GL-USPSTF-DEP-2023S
Staging by FIGO 1843 with pelvic MRI and PET-CT, and a CT-guided biopsy of a lung nodule; tumor PD-L1, mismatch repair and HER2 testing; no germline testing, because cervical cancer is not a hereditary cancer syndromecompletedGL-NCCN-CERV-2026, GL-FIGO-2018S
Palliative pelvic radiation, 20 Gy in 5 fractions, for bleeding and pain, then carboplatin, paclitaxel and pembrolizumab every 3 weeks for six cycles with pembrolizumab continuing, without bevacizumab while bleeding and after pelvic radiation; blood counts before each cycle and thyroid tests every six weekscompletedGL-NCCN-CERV-2026, GL-KN826-2021S
Specialist palliative care alongside cancer treatment from diagnosis, for pain, symptoms, mood, and goals-of-care conversations, with long-acting morphine 15 mg every 12 hours and oral morphine 5 mg as needed for breakthrough paincompletedGL-ASCO-PALL-2024, GL-ASCO-OPIOID-2023, GL-ASCO-COMM-2026S

Goals

GoalTargetStatusOutcomeProvenance
Average pelvic pain at or below 3 of 10 without daytime sedation1851-07-14completedAverage pain 3 of 10 after radiation, on long-acting morphine, without daytime sleepinessS
Bleeding controlled and hemoglobin above 10 g/dL without transfusion1851-09-08completedNo bleeding since radiation; hemoglobin 10.6 g/dLS
A documented goals-of-care conversation and a named health care agent1851-09-08completedAdvance care plan and goals-of-care conversation recordedS
Able to work on her mathematics for at least two hours most mornings1851-10-20completedWorking most morningsS

Functional Status

Mental Status